Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from SSY Group ( (HK:2005) ) is now available.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of Paracetamol Granules, a type 3 chemical drug specifically designed for children. This approval grants the company exclusive rights among PRC entities to produce this medication, which is used to treat fever and mild to moderate pain in children, potentially enhancing its market position and offering new opportunities for growth.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is known for its range of pharmaceutical products, with a particular emphasis on the Chinese market.
Average Trading Volume: 12,948,809
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.2B
See more insights into 2005 stock on TipRanks’ Stock Analysis page.